0.05Open0.05Pre Close0 Volume179 Open Interest0.50Strike Price0.00Turnover368.79%IV64.18%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.4165Delta1.6494Gamma6.72Leverage Ratio-0.0035Theta0.0000Rho2.80Eff Leverage0.0003Vega
Renovaro Stock Discussion
Renovaro's New AI Partnership Targets Breakthrough in Early-Stage Lung Cancer Detection Technology
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
Tuesday, 22nd April at 9:20 am
LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients, today announced is expanding our ongoing strategic collaboration with Nebul (www.nebul.com), a leadi...
Major AI Breakthrough: Renovaro-BioSymetrics Merger Creates Powerhouse in Precision Medicine
Merger Crisis: Renovaro Threatens Legal Action After Predictive Oncology Backs Out
Can Renovaro's AI Oncology Merger Unlock Value From 150,000+ Tumor Samples?
Can Renovaro's AI Biotech Merger Transform Drug Discovery? Major Pharma Already Onboard
No comment yet